To find an approach to prolong the survival time of cardiac allografts in a BALB/c-to-C57/BL6 heterotopic heart transplant model and to try to figure out related chemokines and cytokines, isogeneic and allogeneic BM cells were obtained from pregnant C57/BL6 (~C57/BL6 Â #BALB/c) and regular BALB/c mice and injected to the half lethally irradiated C57/BL6 mice 1 day before heart transplantation. Recipients were treated with CsA or phosphate-buffered saline for 7 days. Isogeneic BMT (iBMT) from pregnant C57/BL6 mice was observed to significantly prolong the survival of BALB/c allografts and reduce the lymphocyte infiltration. Allogeneic BMT (aBMT) and iBMT both exhibited signicantly less T-cell proliferation reactivity and the similar degree of chimerism. There was no significant difference in these groups of IFN-g and IL-4 production. The level of chemokine MIG (CXCL9) dramatically decreased in aBMT and iBMT groups compared with the control group. But there were no significant differences between aBMT and iBMT group. IL-17 and RORg(t) (receptor-related orphan receptor) production were downregulated in iBMT recipients. These results indicate that iBMT can prolong the survival of cardiac allografts. IL-17 production downregulated in iBMT recipients. This means that iBMT may have important therapeutic implications.
INTRODUCTION
The survival of solid-organ transplants has been improved with development of immunosuppressive therapy. However, long term use of immunosuppressants has been associated with increased risk of life-threatening infections 1 and malignancies. 2 To avoid the need of lifelong immunosuppressive treatment, alternative approaches to effectively prevent rejection have been developed including induction of immunological tolerance to the allograft. The establishment of chimerism by transplanting donor-derived BM cells (BMCs) has been shown to lead to tolerance of the transplanted allograft both preclinically 3 and clinically. 4 However, there are still lots of issues about how to effectively make the recipients accept the donor BMCs. Usually, myeloablation or depletion of immune cells are needed to condition the recipient for mismatched BMT. But these would increase the risks of unwanted toxicities such as GVHD, which is a signicant problem when attempting to establish chimeras.
Recently, Joffre et al. 5 found regulatory T cells (Tregs) can be used to prevent acute and chronic rejection of skin and cardiac allografts. But Tregs alone without BM infusion failed to induce tolerance to skin allografts. Maybe BM had some other important role not just deleting the alloreactive T cell clones in this approach.
In this study, we found a potential approach to prolong the survival of cardiac allografts in a BALB/c to C57/BL6 heterotopic heart transplant model without myeloablation or cytoreductive treatments. Furthermore, we also tried to figure out the associated cytokines and chemokines in this approach.
MATERIALS AND METHODS Animals
Adult female/male C57BL/6 (H-2b) and female/male BALB/c (H-2d) mice of 6 --12 weeks (20 --25 g) were used in this research. The mice were housed (in a specific pathogen-free animal facility) under conventional conditions and fed water and standard rodent laboratory chow. All animals received humane care in compliance with institutional animal care-approved criteria and protocols.
BMT and heart allotransplantation Isogeneic BM was flushed from the femurs and tibias of the pregnant C57BL/6 mice (~C57 Â #BALB/c), which had been crossed with BALB/c mice and had identical genotype with the recipient C57BL/6 mice. Allogeneic BM was obtained from regular female BALB/c mice, which had different genotype with the recipient C57BL/6 mice. Control phosphatebuffered saline (PBS) and BMCs (1 --5 Â 10 6 ) lysed with erythrocytes were injected into the femoral vein of the half lethally irradiated (2Gy, 12 h before) C57BL/6 recipient mice. After 1 day, recipient mice were transplanted with allogeneic BALB/c hearts.
Heart allotransplantation was performed between whole MHC-incompatible male BABL/c (donors) and male C57/BL6 (recipients) mice as described previously. 6 Briefly, the aorta and pulmonary artery of the donor heart were anastomosed end-to-side to the recipient's abdominal aorta and inferior vena cava, respectively. Upon perfusion with the recipient's blood, the transplanted heart spontaneously resumed contractions within 30 s after reperfusion. Graft function was monitored by abdominal palpation daily and rejection was defined as complete arrest of contractility. Cessation of contractility was confirmed by direct visualization.
Experimental group
There were six experimental groups in this study (Table 1) : group I (n ¼ 5) control group, C57BL/6 recipient mice received PBS i.v. 1 day before the heart transplantation and then treated with PBS intragastrically for 7 days; group II (n ¼ 5) CsA group, recipient mice received PBS i.v. 1 day before the heart transplantation and then treated with CsA (1 mg/kg) intragastrically for 7 days using a similar protocol; group III (n ¼ 7) allogenetic BMT (aBMT) group, C57BL/6 recipient mice received allogenetic BMCs (1 --5 Â 10 6 ) i.v. 1 day before the heart transplantation and then treated with PBS intragastrically for 7 days; group IV (n ¼ 6) aBMT þ CsA group, C57BL/6 recipient mice received aBMCs (1 --5 Â 10 6 ) i.v. 1 day before the heart transplantation and then treated with CsA intragastrically for 7 days; group V (n ¼ 6) Isogeneic BMT (iBMT) group, C57BL/6 recipient mice received isogeneic BMCs (1 --5 Â 10 6 ) i.v. 1 day before the heart transplantation and then treated with PBS intragastrically for 7 days; group VI (n ¼ 5) iBMT þ CsA group, C57BL/6 recipient mice received iBMCs (1 --5 Â 10 6 ) i.v. 1 day before the heart transplantation and then treated with CsA intragastrically for 7 days; the donor hearts were harvested on day 10 post transplant for histological and immunohistochemical analysis.
Histological and immunohistochemical analysis
Allografts were removed and divided in half in long axis perpendicular to the intra-ventricular septum. Grafts were fixed in 10% formalin, embedded in paraffin, sectioned at 3 mm and stained by hematoxylin and eosin for histological analysis.
Immunohistochemical staining was performed using the same sections as described above. The slides were incubated with IL-17 (Santa Cruz Biotechnology, Heidelberg, Germany, sc-7927) Ab (diluted at ratio of 1:200 using PBS/2% BSA), in a humid chamber at 4 1C overnight. The slides were then rinsed three times with PBS and covered with Envision HRP according to Real Envision Detection Kit (GK500705, Shanghai, China). Finally, the slides were dehydrated in ethyl alcohol, viewed under light microscopy and images were captured using Image Pro Plus (Media Cybernetics, Bethesda, MD, USA). Five high-power fields ( Â 400) were counted per slide. Results are presented as mean numbers of cells±s.d. All the slides were examined by the same pathologist.
Flow cytometric determination of chimerism
The establishment of chimeras was evaluated by flow cytometric analysis. To detect the chimerism on leukocytes, cell suspensions were prepared from spleens of graft recipient C57/BL6 mice as well as control naïve C57/BL6 mice. Then the cells were counted and aliquots of 10 6 cells were stained with donor-specific allophycocyanin anti-mouse MHC class I (a3 domain of H-2Kd) (eBioscience, San Diego, CA, USA, 17-5957) for 20 min at room temperature. The cells were washed and analyzed on a flow cytometer (FACSCalibur; BD Biosciences, Franklin Lakes, NJ, USA). Data were analyzed using Flow Jo software (Tree Star, Ashland, OR, USA). For cytokine analysis, sera harvested at 10 days after transplantation from recipients were analyzed by a multiplexed cytokine bead-based immunoassay using a preconfigured 9-plex mouse cytokine detection kit (Luminex, Millipore, Billerica, MA, USA) according to the manufacturer's instructions. ELISA was performed according to R&D standard protocol to measure the concentrations of chemokine MIG/CXCL9, cytokine IFN-g and IL-4 in the recipients' sera.
Mixed leukocyte reaction

Western blot
Protein level of RORg(t) (receptor-related orphan receptor), a transcription factor specically required for Th17 development 8 in the myocardium, was assessed by western blot. Briefly, 50 mg of protein samples were denatured and subjected to a SDS-PAGE and then transferred to a Hybond-ECL nitrocellulose membrane. The blot was incubated with a 1:250 diluted antimouse RORg(t) purified (eBioscience, 14-6981), and then with peroxidesconjugated anti-rat IgG secondary Ab.
Statistics
Data were presented as mean ± s.d. The Kaplan --Meier analysis and Mann --Whitney U test were used for statistical evaluation of graft survival and survival differences between two groups, respectively. Student's unpaired t test was used for evaluation of all other data. Values of Po0.05 were considered statistically significant.
RESULTS
Extended survival of iBMT allografts
To evaluate the effect of aBMT and iBMT on graft survival we treated recipient male C57/BL6 mice who had received sublethally irradiated (2Gy) whole body irradiation on the day before transplantation with a single injection of 0.2 mL PBS, allogenetic BMCs (1 --5 Â 10 6 ) from regular female BALB/c mice or isogeneic BMCs (1 --5 Â 10 6 ) from pregnant C57/BL6 (~C57/BL6 Â #BALB/ c) through femoral vein to the C57/BL6 mice just 1 day before they received the heart allografts from BALB/c. After the transplantation, recipients were treated with CsA (1 mg/kg) or PBS everyday from the first day of transplantation for a week.
Median survival time (MST) of group I (control group) was 10 day after transplant, when recipients of group II (CsA group) were treated with CsA, MST of allograft was clearly extended to 16 days (Po0.05; Figure 1 ). Interestingly MST of group III (aBMT group) was 11 day, similar to group I (P40.05; Table 1, Figure 1 ) and MST of group IV (aBMT þ CsA group) was 15 days that was not significantly different with group II (P40.05; Table 1, Figure 1 ). Whereas MST of group V (iBMT group) was extended much longer to 31 days compared with group I and group III (Po0.05; Table 1 , Figure 1 ) and MST of group VI (iBMT þ CsA group) was 51 days much longer than group II and group IV (Po0.05; Table 1, Figure 1 ) but not significantly longer than group V (P40.05; Table 1, Figure 1) .
These results suggested that 2Gy irradiation plus aBMT just 1 day before heart allotransplantation could not effectively improve the allografts survival whereas iBMT could significantly improve the survival time of heart allografts by the other unknown pathways. 
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Delayed lymphocyte infiltration into allografts of iBMT group Day 10 after transplant (a day of rejection of control group), BALB/c heart allografts were retrieved from C57/BL6 recipients and were stained with hematoxylin and eosin. Examination of sections from allografts of group I indicated intense lymphocyte infiltration with the rejection of the allografts (Figure 2a ). Hematoxylin and eosin of the sections from group II, III and IV looked similar as the control group (Figures 2b --d) . In contrast, group V and group VI showed less cellular infiltration (Figures 2e and f) . These results indicated that iBMT could improve the lymphocyte infiltration of heart allografts.
Decreased T-cell proliferative responses in iBMT recipients The ability of allogeneic BMCs and isogeneic BMCs to suppress lymphocyte proliferation in response to unmatched MHC was tested by mixed leukocyte reaction assay. At day 10 after the transplant, the suspensions of spleen cells from aBMT, iBMT and control recipients were prepared and cocultured with MMCtreated splenocytes from allograft donor wide type BALB/c. Spleen cells from iBMT recipients exhibited signicantly less T cell proliferation reactivity than control of spleen cells from control C57/BL6 (1.10±0.22 vs 8.03±5.66, Po0.05) (Figure 3 ) whereas splenocytes from aBMT showed less T cell proliferation than aBMT could not improve the survival of allograft (group III vs group I, P40.05; group IV vs group II, P40.05). iBMT from pregnant mice could significantly improve the allograft survival of control group (group V vs group I, Po0.01) and CsA group (group V vs group II, Po0.05). iBMT þ CsA could prolong the survival of grafts from 34.3 ± 14.2d to 51.2 ± 13.5d, not significantly (group VI vs group V, P ¼ 0.08).
control but NS (1.54 ± 0.98 vs 8.03 ± 5.66, P ¼ 0.061) (Figure 3 ). There was also no obvious difference between aBMT and iBMT in mixed leukocyte reaction (P40.05; Figure 3 ).
Degree of chimerism
Previous studies have shown that recipients who received donor-derived BMCs generally develop chimerism. 3 To determine the degree of chimerism in aBMT and iBMT cardiac allograft recipients, splenocytes were isolated at day 10 after transplant and stained with allophycocyanin-conjugated mAbs against mouse MHC class I and analysed by using Flow Cytometry. The degree of chimerism of iBMT recipient mice was 5.87 ± 3.31%, which was similar with aBMT recipient mice 4.73±1.11% (P40.05; Figure 4 ).
Cytokines and chemokines analysis by luminex
In this study, we selected nine cytokines and chemokines associated with rejection analysed by Luminex. We found there were no significant changes of IFN-g, IL-4, IL-2, VEGF, but IL-17, IL-6, IL-10, RANTES and MIG were obvious decreased in group III, IV, V and VI compared with group I (Figure 5 ). Although there were no significant differences between iBMT (group V, VI) and aBMT (group III, IV) ( Figure 5 ).
No significant change of Th1 and Th2 cytokine production by iBMT recipients Since IFN-g is mainly produced by Th1 cells. IFN-g in the sera of these six groups was also measured with ELISA. No significant difference of IFN-g level among these groups was observed (Figure 6a) . IL-4 is the major immunoregulatory and immunosuppressive cytokine produced by Th2 cells and has a pivotal role in downregulating immune responses and inducing the potential anti-inflammatory effect. 9 --11 So the level of IL-4 was also reassessed by ELISA. Interestingly, IL-4 in these groups was not significantly different (Figure 6b ). Downregulation of chemokine Mig (CXCL9) in aBMT and iBMT recipients MIG (CXCL9), a potent chemotactic factor for T lymphocytes, has been shown to contribute to various inflammatory disorders. 12 Miura et al. 13 demonstrated that MIG (CXCL9) is a dominant factor in recruitment of T lymphocytes in the acute rejection of MHCmismatched cardiac allografts. Our Luminex results showed that MIG (CXCL9) level was significantly reduced in iBMT and aBMT recipients ( Figure 5 ). So MIG (CXCL9) in the sera of these groups was remeasured by ELISA.
MIG (CXCL9) in the control group was significantly higher compared with the wide type C57/BL6 (400.78±216.37 vs 74.67±33.36, Po0.01; Figure 7 ). When compared with the control group, aBMT, aBMT þ CsA, iBMT and iBMT þ CsA group except the CsA group, the production of MIG (CXCL9) was dramatically decreased (Po0.01; Figure 7 ). But there were no significant differences between aBMT and iBMT. These results indicated that although the rejection of single class II MHC disparate heart allografts in the C57/BL6 and BALB/c combination may be promoted by the production of MIG (CXCL9), extended survival of iBMT allografts was not because of the downregulation of MIG (CXCL9). Downregulation of Th17 cytokine and its transcription factor RORc(t) production by iBMT recipients Since IL-17-producing Th17 serves to amplify the inflammatory responses and IL-17 has also recently been implicated as a profibrotic cytokine 14, 15 and IL-17 was significantly reduced in iBMT recipients compared with the control group according to the results of Luminex in our study (39.5 ± 30.4 vs 172.4 ± 142.9, Po0.05; Figure 5a ). So we decided to test the level of Th17 and its transcription factor in iBMT group. We used immunohistochemical staining to half-quantify the IL-17 expression in the cardiac allografts.
Further, allografts harvested from iBMT and iBMT þ CsA groups 10 days after transplant were notable for much less IL-17 positive leukocyte infiltration, which was much higher in the control group We also used western blot to examine the level of transcription factor of Th17 RORg(t). Elevated RORg(t) protein expression was observed in untreated control and CsA group (Figure 8b Figure 4 . To determine the degree of chimerism in iBMT cardiac allograft recipients, splenocytes were isolated at day 10 after transplant. The degree of chimerism of (a) iBMT recipient mice was 5.87±3.31% which was similar with (b) aBMT recipient mice 4.73±1.11% (P40.05).
cated even higher expression of RORg(t) protein. At the same time, iBMT and iBMT þ CsA group showed effective reduction of the expression of RORg(t), correlating well with the repression of acute rejection.
DISCUSSION
This study demonstrates that iBMT (in contrast to allogeneic BMT, it was from the same strain mouse C57/BL6 but pregnant, which had been crossed with Balb/c mice) can prolong the survival time of cardiac allograft by reducing IL-17 production in mice. In the past decade, many studies have examined the role of donorderived BMCs in acute allograft rejection preclinically 3 and clinically. 4 Myeloablation or depletion of immune cells (such as whole body irradiation and chemotherapy) is usually reconstituted with allogeneic BMCs for mismatched BMT, but these treatments increase the risks of unwanted toxicities such as GVHD. 16, 17 iBMT might be another attractive method to induce tolerance without the need for lifelong immunosuppression and myeloablation or depletion of immune cells.
According to the results of this study, we found that iBMT signicantly prolonged the survival time without myeloablation or cytoreductive treatments (Figure 1 ), which was confirmed by the histological changes that showed delayed lymphocyte infiltration into allografts of iBMT group (Figure 2) and exhibited less T cell proliferation reactivity than the control group but not significantly than aBMT group (Figure 3) . The degree of chimerism of iBMT recipient mice was similar to aBMT recipient mice (Figure 4) . Although iBMT had less mixed leukocyte reaction and low-level chimerism, it was not significantly different from the aBMT group. aBMT group was not able to improve the survival time of allografts in our study, there were several reasons: first, 2Gy was such a small dose that could not delete alloreactive T cell clones; second, 7 days CsA treatment was not enough for the tolerance to be built; third, cardiac transplant just 1 day after BMT did not give enough time for the chimerism to be formed. Failure to prolong the survival time of aBMT also told us that iBMT could prolong the survival not because of the half lethal irradiation, the CsA treatment or the chimerism.
Furthermore, we tried to figure out the cytokines and chemokines associated in this approach for better understanding of the mechanism of the induction of prolonged survival time of cardiac allografts by iBMT in mice.
Firstly, we noticed that the sera of iBMT mice 10 days post transplant had less chemokines MIG (CXCL9) than that of the control recipients but there were no significant differences between aBMT and iBMT group (Figure 7) . MIG (CXCL9) is a potent chemotactic factor for T lymphocytes, and the importance of MIG (CXCL9) in acute rejection of allografts has been documented. 13, 18 Previous studies demonstrated the survival of skin grafts on C57BL/6 recipients was prolonged when the recipients were treated with MIG (CXCL9)-specific ABs. 19 Our study found both iBMT and aBMT could effectively reduce the production of MIG (CXCL9). These results indicated that though the rejection of single class II MHC disparate heart allografts in the C57/BL6 and BALB/c combination was strongly promoted by the production of MIG (CXCL9), downregulation of MIG (CXCL9) by iBMT recipients was not the main mechanism that iBMT could improve the survival of the allografts. Secondly, our results demonstrated that the sera and cardiac allografts of iBMT mice 10 days post transplant had lower levels of the cytokine IL-17 ( Figures 5 and 8 ). This may suggest that survival of cardiac allograft prolonged by iBMT is achieved by reducing IL-17 production in mice. This hypothesis correlates well with what is known about IL-17. Recent murine experiments showed that CD4 þ Th cells can differentiate into Th17 cells, which produce IL-17 and have a crucial role in inflammation and autoimmune diseases. 20 --22 IL-17 is a potent proinflammatory cytokine that induces chemokine expression and leukocyte infiltration and mediates tissue inflammation. 23 Recent studies report that IL-17 blockade with an anti-IL-17 Ab results in prolongation of allograft survival in a skin transplantation model. 24 Yuan et al. 25 showed that accelerated chronic rejection could be attenuated with either IL-17-neutralizing Ab or CD4 þ T cell depletion (Th1, Th2, Th17 and Treg cells). However, the role of Th17 and its cytokine IL-17 in the transplant condition was examined in very few studies. It was reported that the Th17/Treg imbalance might be involved in the development of allograft rejection. 26 Joffre et al. 5 showed that Tregs could be used to prevent acute and chronic rejection of skin and cardiac allografts. In our study isogeneic BMCs was isolated from pregnant C57/BL6 (~C57/BL6 Â #BALB/c) stimulated by donor BALB/c, maybe Tregs also participated in this approach. Maybe BMT had some other important role similar with Tregs not just deleting the alloreactive T cell clones in this approach. In mice, the differentiation of Th17 cells from naive CD4 þ T cells requires TGF-b and IL-6. TGF-b induces the expression of the RORg(t) and also induces forkhead box p3, which is the essential transcription factor for the differentiation and function of Treg cells. Fork-head box p3 inhibits RORg(t)-directed IL-17 expression through binding to RORg(t). 27 So we can see that there is close relationship between Th17 and Treg. Tregs have traditionally been thought to be generated exclusively in the thymus, whereas there is mounting evidence that fork-head box p3 þ Treg cells can develop extrathymically under certain conditions. Human BM contains a higher frequency of Treg cells than other secondary lymphoid organs. Joji et al. 28 confirmed that the frequency of fork-head box p3 Treg cells in CD4 T cells is higher in the BM (23%) than in the spleen (13%) and lymph nodes (13%). Studies have emphasized the role of the BM as a major priming site for T cell response. Anyway, further investigations on exploration of the Th17 mechanism and its mechanisms in iBMT need to be performed in the future.
At last, no significant change of Th1 and Th2 cytokine production 10 days post transplant was observed in the sera of iBMT recipients ( Figure 6 ). As we all know, Th cells were traditionally classified as Th1 and Th2 cells based on their cytokine-expression profiles. 29 In particular, Th1 cells produce IFN-g, which enhances cellular immunity and is required for the clearance of intracellular organisms. On the other hand, Th2 cells produce IL-4, which prolongs allograft survival and synergizes with other immunosuppressive agents. 30 --32 Although in some other studies it has no effect on graft survival. 33 --35 Our study suggested iBMT cannot protect the allografts from the rejection by influencing Th1 or Th2 cells.
In conclusion, this study demonstrates that iBMT from pregnant C57/BL6 (~C57 Â #BALB/c) can prolong the survival time of cardiac allografts and reduce cytokine IL-17 production in mice. This suggests that tolerant status induced by pregnancy, which was natural immune tolerance could be transmitted by BMT. iBMT Figure 7 . MIG (CXCL9) was remeasured by ELISA. MIG (CXCL9) in the control group was significantly increased than the wide type C57/ BL6 (400.78 ± 216.37 vs 74.67 ± 33.36, Po0.01). Except the CsA group, the production of MIG (CXCL9) was dramatically decreased in the other four groups including aBMT, aBMT þ CsA, iBMT and iBMT þ CsA group compared with the control group (90.52 ± 83.45 vs 400.78 ± 216.37, 93.18 ± 57.78 vs 400.78 ± 216.37, 42.73 ± 16.51 vs 400.78 ± 216.37, 66.61 ± 41.88 vs 400.78 ± 216.37, Po0.01 respectively). But there were no significant differences between aBMT and iBMT group. *Po0.01, vs control group. Figure 8 . IL-17 and RORg(t) production downregulated in iBMT recipients. (a) IL-17 activity expression in the cardiac allografts was measured by immunohistochemical staining (400 Â ). iBMT and iBMT þ CsA group were notable for much less IL-17 positive leukocyte infiltration than the control group (Po0.01). aBMT and aBMT þ CsA group were also less IL-17 positive leukocyte infiltration than the control but not significantly (P40.05). (b) iBMT and iBMT þ CsA group showed effective reduction of the expression of RORg(t). *Po0.01, vs control group.
